MAIA Biotechnology, Inc. (MAIA)

1.4 0.05 (3.7%)

As of 2025-10-16 18:57:38 EST

MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.

Traded asNYSE: MAIA
ISINUS5526411021
CIK0001878313
LEI—
EIN—
Sector—
IndustryPharmaceutical Preparations
CEOVlad Vitoc
Employees—
Fiscal Year End1231
Address444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
Phone312-416-8592
Websitehttps://maiabiotech.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
MAIAMAIA Biotechnology, Inc.2025-10-16 18:57:381.40.053.7
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
MAIA0001878313MAIA Biotechnology, Inc.US5526411021——NYSE2834Pharmaceutical Preparations1231DE444 WEST LAKE STREET, SUITE 1700CHICAGOIL60606UNITED STATESUS312-416-8592444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606———Vlad Vitoc—https://maiabiotech.com/67,463,30031,818,48032,993,220MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.2025-10-10 23:18:43
This is a preview of the latest data. Subscribe to access the full data.
MAIA Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
MAIA Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202467,463,30044,979,100200.047629,587,3149,584,48847.9157
202322,484,20022,484,20010020,002,8269,006,42281.9033
20220010010,996,40410,996,404100
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Sergei GryaznovChief Scientific Officer2024363,000145,200——13,461929,838
Vlad VitocPresident, Chief Executive Officer2024473,000236,500——13,4611,360,441
Joseph F. McguireChief Financial Officer2023284,1670——96,431844,814
Sergei GryaznovChief Scientific Officer2023363,0000——54,334894,749
Vlad VitocPresident, Chief Executive Officer2023473,0000——56,8231,430,757
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202413
202313
202218
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses10,009,22911,112,2578,933,314
General And Administrative Expenses6,947,9819,070,1246,143,527
Operating Expenses16,957,21020,182,38116,176,201
Operating Income-16,957,210-20,182,381-16,176,201
Net Income-23,254,656-19,772,905-15,769,279
Earnings Per Share Basic-1.05-1.49-1.75
Earnings Per Share Diluted-1.05-1.49-1.75
Weighted Average Shares Outstanding Basic22,197,51713,261,5729,276,761
Weighted Average Shares Outstanding Diluted22,197,51713,261,5729,276,761
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents000
Marketable Securities Current———
Accounts Receivable———
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current10,152,4797,564,05211,808,037
Marketable Securities Non Current———
Property Plant And Equipment———
Other Assets Non Current2,8002,8002,800
Total Assets Non Current2,8002,800214,003
Total Assets10,155,2797,566,85212,022,040
Accounts Payable1,512,4361,638,5461,165,505
Deferred Revenue———
Short Term Debt———
Other Liabilities Current2,317,6023,298,6072,103,401
Total Liabilities Current3,830,0384,937,1533,268,906
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current2,690,6052,152,188245,341
Total Liabilities6,520,6437,089,3413,514,247
Common Stock2,6161,6991,096
Retained Earnings-87,234,833-63,980,177-44,207,272
Accumulated Other Comprehensive Income-30,615-16,260-15,973
Total Shareholders Equity3,634,636477,5118,507,793
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization———
Share Based Compensation Expense1,912,7443,089,3042,319,427
Other Non Cash Income Expense———
Change In Accounts Receivable—-158,405269,395
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets——-322
Change In Accounts Payable-118,827471,897211,346
Change In Other Liabilities-979,7922,169,921915,742
Cash From Operating Activities-15,704,461-13,071,016-11,655,725
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment———
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-21,545-117-4,430
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock2,920,696—2,473,560
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities18,176,6099,270,90112,036,790
Change In Cash2,450,603-3,800,232376,635
Cash At End Of Period000
Income Taxes Paid———
Interest Paid576,8636,967
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year20242023
Earnings Per Share-1.05-1.49
Price To Earnings Ratio-1.8857-0.7852
Earnings Growth Rate-29.5302-14.8571
Price Earnings To Growth Ratio0.06390.0529
Book Value Per Share0.16370.036
Price To Book Ratio12.092332.4936
Ebitda——
Enterprise Value——
Dividend Yield——
Dividend Payout Ratio——
Debt To Equity Ratio——
Capital Expenditures——
Free Cash Flow——
Return On Equity-6.3981-41.4083
One Year Beta1.13650.8427
Three Year Beta0.53390.3022
Five Year Beta0.53390.3022
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
CHAOUKI STEVEN MDirector2025-10-0220,946A20,946
Guerrero RamiroDirector2025-10-0220,459A20,459
Louie Ngar YeeDirector2025-10-0225,331A25,331
Luput CristianDirector2025-10-0221,434A21,434
Theagene Jean-ManasseDirector2025-10-0220,459A20,459
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
OSAIC HOLDINGS, INC.2025-06-3015,0018,3341.8
MORGAN STANLEY2025-06-309,1715,0951.8
Tower Research Capital LLC (TRC)2025-06-303,3251,8471.8002
RAYMOND JAMES FINANCIAL INC2025-06-301801001.8
JANE STREET GROUP, LLC2025-06-3051,81028,7831.8
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
iSHARES TRUST2025-06-30iShares Micro-Cap ETFIWC50,92991,672.20.0112
VANGUARD INDEX FUNDS2025-06-30Institutional Select SharesVSEMX533,324959,983.20.0008
VANGUARD INDEX FUNDS2025-06-30Institutional Plus SharesVEMPX533,324959,983.20.0008
VANGUARD INDEX FUNDS2025-06-30ETF SharesVXF533,324959,983.20.0008
VANGUARD INDEX FUNDS2025-06-30Institutional SharesVIEIX533,324959,983.20.0008
This is a preview of the latest data. Subscribe to access the full data.